332 related articles for article (PubMed ID: 22142287)
21. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH
Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
[TBL] [Abstract][Full Text] [Related]
22. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
[TBL] [Abstract][Full Text] [Related]
23. High vancomycin MICs predict the development of infective endocarditis in patients with catheter-related bacteraemia due to methicillin-resistant Staphylococcus aureus.
San-Juan R; Fernández-Ruiz M; Gasch O; Camoez M; López-Medrano F; Domínguez MÁ; Almirante B; Padilla B; Pujol M; Aguado JM;
J Antimicrob Chemother; 2017 Jul; 72(7):2102-2109. PubMed ID: 28379553
[TBL] [Abstract][Full Text] [Related]
24. Impact of reduced vancomycin MIC on clinical outcomes of methicillin-resistant Staphylococcus aureus bacteremia.
Park SY; Oh IH; Lee HJ; Ihm CG; Son JS; Lee MS; Kim MN
Antimicrob Agents Chemother; 2013 Nov; 57(11):5536-42. PubMed ID: 23979741
[TBL] [Abstract][Full Text] [Related]
25. Early response assessment to guide management of methicillin-resistant Staphylococcus aureus bloodstream infections with vancomycin therapy.
Joo J; Yamaki J; Lou M; Hshieh S; Chu T; Shriner KA; Wong-Beringer A
Clin Ther; 2013 Jul; 35(7):995-1004. PubMed ID: 23829982
[TBL] [Abstract][Full Text] [Related]
26. Predictive factors for mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infection: impact on outcome of host, microorganism and therapy.
Gasch O; Camoez M; Dominguez MA; Padilla B; Pintado V; Almirante B; Molina J; Lopez-Medrano F; Ruiz E; Martinez JA; Bereciartua E; Rodriguez-Lopez F; Fernandez-Mazarrasa C; Goenaga MA; Benito N; Rodriguez-Baño J; Espejo E; Pujol M;
Clin Microbiol Infect; 2013 Nov; 19(11):1049-57. PubMed ID: 23331461
[TBL] [Abstract][Full Text] [Related]
27. High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis.
Jacob JT; DiazGranados CA
Int J Infect Dis; 2013 Feb; 17(2):e93-e100. PubMed ID: 23089040
[TBL] [Abstract][Full Text] [Related]
28. Predictors of clinical and microbiological treatment failure in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: a retrospective cohort study in a region with low MRSA prevalence.
Forstner C; Dungl C; Tobudic S; Mitteregger D; Lagler H; Burgmann H
Clin Microbiol Infect; 2013 Jul; 19(7):E291-7. PubMed ID: 23490021
[TBL] [Abstract][Full Text] [Related]
29. Phenotypic changes of methicillin-resistant Staphylococcus aureus during vancomycin therapy for persistent bacteraemia and related clinical outcome.
Kim T; Kim ES; Park SY; Sung H; Kim MN; Kim SH; Lee SO; Choi SH; Jeong JY; Woo JH; Chong YP; Kim YS
Eur J Clin Microbiol Infect Dis; 2017 Aug; 36(8):1473-1481. PubMed ID: 28337607
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors associated with 30-day in-hospital mortality in coagulase-negative Staphylococcus bacteraemia: no impact of vancomycin minimum inhibitory concentration.
Hentzien M; Strady C; Vernet-Garnier V; Servettaz A; De Champs C; Delmer A; Bani-Sadr F; N'Guyen Y
Infect Dis (Lond); 2017 Sep; 49(9):664-673. PubMed ID: 28490261
[TBL] [Abstract][Full Text] [Related]
31. Clinical and microbiological factors associated with early patient mortality from methicillin-resistant Staphylococcus aureus bacteremia.
Kim T; Chong YP; Park KH; Bang KM; Park SJ; Kim SH; Jeong JY; Lee SO; Choi SH; Woo JH; Kim YS
Korean J Intern Med; 2019 Jan; 34(1):184-194. PubMed ID: 28859468
[TBL] [Abstract][Full Text] [Related]
32. Vancomycin MICs do not predict the outcome of methicillin-resistant Staphylococcus aureus bloodstream infections in correctly treated patients.
Rojas L; Bunsow E; Muñoz P; Cercenado E; Rodríguez-Créixems M; Bouza E
J Antimicrob Chemother; 2012 Jul; 67(7):1760-8. PubMed ID: 22556382
[TBL] [Abstract][Full Text] [Related]
33. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
Song KH; Kim HB; Kim HS; Lee MJ; Jung Y; Kim G; Hwang JH; Kim NH; Kim M; Kim CJ; Choe PG; Chung JY; Park WB; Kim ES; Park KU; Kim NJ; Kim EC; Oh MD
Int J Antimicrob Agents; 2015 Dec; 46(6):689-95. PubMed ID: 26555059
[TBL] [Abstract][Full Text] [Related]
34. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
Soriano A; Marco F; Martínez JA; Pisos E; Almela M; Dimova VP; Alamo D; Ortega M; Lopez J; Mensa J
Clin Infect Dis; 2008 Jan; 46(2):193-200. PubMed ID: 18171250
[TBL] [Abstract][Full Text] [Related]
35. High vancomycin minimum inhibitory concentration is associated with poor outcome in patients with methicillin-susceptible Staphylococcus aureus bacteremia regardless of treatment.
Castón JJ; González-Gasca F; Porras L; Illescas S; Romero MD; Gijón J
Scand J Infect Dis; 2014 Nov; 46(11):783-6. PubMed ID: 25134647
[TBL] [Abstract][Full Text] [Related]
36. Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia.
Clemens EC; Chan JD; Lynch JB; Dellit TH
Diagn Microbiol Infect Dis; 2011 Dec; 71(4):408-14. PubMed ID: 21924852
[TBL] [Abstract][Full Text] [Related]
37. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization.
Brown J; Brown K; Forrest A
Antimicrob Agents Chemother; 2012 Feb; 56(2):634-8. PubMed ID: 22123681
[TBL] [Abstract][Full Text] [Related]
38. Is there a clinical association of vancomycin MIC creep, agr group II locus, and treatment failure in MRSA bacteremia?
de Sanctis JT; Swami A; Sawarynski K; Gerasymchuk L; Powell K; Robinson-Dunn B; Carpenter CF; Sims MD
Diagn Mol Pathol; 2011 Sep; 20(3):184-8. PubMed ID: 21817905
[TBL] [Abstract][Full Text] [Related]
39. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.
Moore CL; Osaki-Kiyan P; Haque NZ; Perri MB; Donabedian S; Zervos MJ
Clin Infect Dis; 2012 Jan; 54(1):51-8. PubMed ID: 22109947
[TBL] [Abstract][Full Text] [Related]
40. Early Administration of Adjuvant β-Lactam Therapy in Combination with Vancomycin among Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Infection: A Retrospective, Multicenter Analysis.
Casapao AM; Jacobs DM; Bowers DR; Beyda ND; Dilworth TJ;
Pharmacotherapy; 2017 Nov; 37(11):1347-1356. PubMed ID: 28949410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
